X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3881) 3881
Book Chapter (89) 89
Dissertation (32) 32
Conference Proceeding (16) 16
Publication (15) 15
Magazine Article (2) 2
Book / eBook (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
α-synuclein (3575) 3575
alpha-synuclein (2712) 2712
parkinson's disease (2065) 2065
humans (2015) 2015
neurosciences (1695) 1695
animals (1298) 1298
parkinsons-disease (1268) 1268
alpha-synuclein - metabolism (1251) 1251
parkinson’s disease (910) 910
biochemistry & molecular biology (828) 828
lewy bodies (781) 781
male (727) 727
neurodegeneration (724) 724
alzheimers-disease (657) 657
alpha-synuclein - genetics (632) 632
neurodegenerative diseases (619) 619
parkinson disease - metabolism (608) 608
mice (602) 602
clinical neurology (597) 597
aggregation (553) 553
pathology (536) 536
synuclein (532) 532
female (520) 520
proteins (516) 516
α‐synuclein (511) 511
mutation (505) 505
oxidative stress (484) 484
aged (454) 454
dementia (447) 447
parkinson disease - pathology (437) 437
nervous system (429) 429
brain (414) 414
nervous system diseases (410) 410
neurology (406) 406
dopamine (381) 381
parkinson disease - genetics (375) 375
alpha-synuclein - chemistry (374) 374
movement disorders (355) 355
neurons (355) 355
multiple system atrophy (354) 354
brain - metabolism (344) 344
neurons - metabolism (337) 337
middle aged (328) 328
synucleins (328) 328
cell biology (324) 324
protein (318) 318
alzheimer's disease (299) 299
rats (292) 292
brain - pathology (288) 288
aged, 80 and over (270) 270
in-vitro (266) 266
autophagy (261) 261
disease models, animal (256) 256
tau (248) 248
phosphorylation (246) 246
substantia-nigra (243) 243
pathogenesis (239) 239
immunohistochemistry (226) 226
nerve tissue proteins - metabolism (223) 223
biophysics (219) 219
expression (214) 214
parkinsons disease (206) 206
neurons - pathology (205) 205
parkinson disease (200) 200
disease (198) 198
lewy body (195) 195
mice, inbred c57bl (195) 195
amyloid (186) 186
apoptosis (184) 184
analysis (171) 171
mice, transgenic (158) 158
animal diseases (153) 153
dopamine - metabolism (149) 149
oligomers (149) 149
neurotoxicity (145) 145
adult (144) 144
protein aggregation (144) 144
cell line, tumor (142) 142
biomedicine (140) 140
lewy bodies - pathology (137) 137
toxicity (136) 136
binding (134) 134
dementia with lewy bodies (132) 132
lewy bodies - metabolism (132) 132
cells, cultured (128) 128
dopaminergic-neurons (127) 127
transgenic mice (123) 123
nerve tissue proteins - genetics (122) 122
parkinson disease - physiopathology (122) 122
mouse model (118) 118
substantia nigra (117) 117
lewy body disease (116) 116
protein folding (116) 116
protein binding (114) 114
mental disorders (112) 112
pharmacology & pharmacy (111) 111
a-beta component (107) 107
biomarkers (105) 105
review (105) 105
cell-death (104) 104
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3906) 3906
Chinese (72) 72
Japanese (44) 44
French (12) 12
German (11) 11
Korean (11) 11
Polish (4) 4
Spanish (3) 3
Hungarian (2) 2
Portuguese (2) 2
Russian (2) 2
Czech (1) 1
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


FEBS letters, ISSN 0014-5793, 2011, Volume 585, Issue 3, pp. 561 - 566
Journal Article
Movement disorders, ISSN 0885-3185, 08/2017, Volume 32, Issue 8, pp. 1117 - 1130
Journal Article
Movement disorders, ISSN 1531-8257, 2019, Volume 34, Issue 8, pp. 1154 - 1163
Background Pathological and genetic evidence implicates toxic effects of aggregated α‐synuclein in the pathophysiology of neuronal dysfunction and degeneration... 
synucleinopathy | pharmacokinetics | phase I | Parkinson's disease | α‐synuclein | α-synuclein | DIAGNOSIS | SCALE | alpha-synuclein | CLINICAL NEUROLOGY | PARKINSONS-DISEASE | EKG | Neuroimaging | Neurodegenerative diseases | Parkinsons disease | Clinical trials | Cerebrospinal fluid | Synuclein | Immunotherapy | Monoclonal antibodies | Degeneration | Pharmacokinetics | Movement disorders | s
Journal Article
Movement disorders, ISSN 0885-3185, 2018, Volume 33, Issue 4, pp. 568 - 574
An urgent need for efficacious disease modifying therapies is required to slow downParkinson’s disease (PD) progression. Iron is required as a cofactor in... 
conservative iron chelation | Parkinson's disease | ferroptosis | α‐synuclein | dopamine oxidative stress | α-synuclein | HOMEOSTASIS | DEMENTIA | MARKER | CHELATORS | SUSCEPTIBILITY | MOUSE | NEURODEGENERATION | MICE | ASSOCIATION | BRAIN | CLINICAL NEUROLOGY | Neurodegenerative diseases | Movement disorders | Life Sciences
Journal Article
Biology of the cell, ISSN 1768-322X, 2019, Volume 111, Issue 6, pp. 161 - 168
Parkinson's disease is the second most common neurodegenerative disorder, leading to the progressive decline of motor control due to the loss of dopaminergic... 
Parkinson's disease | Proteostasis | α‐synuclein | Endoplasmic reticulum | Unfolded protein response | α-synuclein
Journal Article